This rule has solidified the notion that providing prescription price transparency at the point-of-care is an essential step in improving the patient financial experience. In particular, the rule will benefit patients who want to understand their out-of-pocket drug costs, and providers who want to reduce time completing administrative tasks (like prior authorizations) and improve patient financial conversations.
So, what does this all mean?
Here is our take on the Who, What, Where, When and Why of the CMS RTBT Final Rule.
Who does the Final Rule (FR) apply to?
The FR applies to Medicare Part D sponsors. These sponsors are typically private insurance plans who are contracted with the government to offer prescription drug coverage for millions of Americans. Those individuals who are enrolled in Medicare are able sign up for supplemental Part D insurance that offers coverage specifically for prescription medicines. Prior to Part D plans being available in 2003, Medicare recipients had little help when paying for retail drugs and therapeutics.
While the FR applies to organizations offering Medicare Part D coverage, it does not apply to healthcare prescribers or health systems (yet) due to the fact that there is no defined standard for RTBTs quite yet, and there is often a lack of trust in the data provided from RTBTs. CMS – and RxRevu – believe that prescribers will only use a RTBT if it is useful, reliable, and accurate, and that price transparency requirements will expand beyond Part D sponsors in the coming years.
What is a RTBT and How Does a Plan Become Compliant?
A RTBT, which the industry often refers to as “Real-Time Benefit Check” or “Real-Time Prescription Benefit,” is an electronic prescription decision support tool that can help to significantly lower patient’s out-of-pocket expenses. These tools are most often used by doctors who prescribe drugs, and typically connect directly with payer and PBM data to present accurate patient coverage information in real-time. This allows for better prescriber-patient conversations, fewer call-backs for prior authorizations, and less prescription abandonment at the pharmacy. Early CMS data reveals that 45% of the time, RTBTs are able to save an average of $130 per patient.
According to CMS, compliance with the FR requires a sponsor to use a RTBT that includes (1) patient-specific utilization requirements (e.g. Prior Authorization or Step Therapy Requirements) that have not been satisfied at the time of prescribing; and (2) patient out-of-pocket costs at the patient’s selected pharmacy. Part D plans must ensure that the RTBT vendor that they select is “patient-specific, timely, and accurate.”
Where does a Part D Sponsor Implement the RTBT?
A sponsor’s RTBT must be capable of integrating with at least one prescriber’s electronic prescribing (eRx) system or electronic health record (EHR). For example, RxRevu’s RTBT presents drug cost information at over 320 hospital systems and is integrated through numerous EHRs, so a sponsor who works with us would be compliant with this portion of the FR.
An “electronic prescribing system” allows healthcare providers to enter prescription information into a computer device – like a tablet, laptop, or desktop computer – and securely transmit the prescription to pharmacies using a special software program and connectivity to a transmission network. An “electronic health record” is a digital version of a patient’s paper chart and medical history. EHRs are real-time, patient-centered records that make information available instantly and securely to authorized users.
When does the New FR Go Into Effect?
Originally, the FR was meant to go into effect January 1, 2020, but due to significant pushback from sponsors, the effective date was pushed back to January 1, 2021. However, CMS estimates 30-90% of Part D plans already have a RTBT, or the ability to easily implement one without a heavy lift or significant financial burden.
It is also worth noting that President Trump’s Hospital Transparency Final Rule will also go into effect January 1, 2021, although there is likely to be pushback from hospitals and other stakeholders before this Rule will go into effect.
Why is a RTBT Necessary and Why is RxRevu the Best Option?
Providing prescription drug price transparency at the point-of-care has been an uphill battle for decades. But CMS’ Final Rule highlights the fact that implementing a RTBT is a critical step in improving patient financial conversations and lowering patients’ out-of-pocket costs. As an added benefit, CMS also anticipates that utilizing a RTBT will help to improve medication adherence since on average, 30% of prescriptions do not get filled by patients, partly due to cost.
Now why might this rule be important if you are a hospital or health system? The FR reaffirms the industry trend towards price transparency. Not only have patients wanted this level of information for years, but now sponsors will be required to provide accurate pricing to their members. This requirement will surely be passed on to health systems that work with these sponsors, since patients covered by these sponsors will expect their doctors to provide accurate prescription pricing.
“CMS is delivering on price transparency, because patients have a right to know the cost of their healthcare services before they receive them,” said CMS administrator Seema Verma. The Rule “requires Part D plans to adopt tools that provide clinicians the information that they can discuss with patients on out-of-pocket costs for prescription drugs at the time a prescription is written.”
RxRevu has been working closely with health systems, payers/PBMs, and EHR vendors to develop the most comprehensive real-time benefit check network in the market – bringing accurate out-of-pocket cost data into the hands of physicians. With over 320 health systems using our tool and unparalleled payer coverage, we are well equipped to support plans and health systems as they prepare for 2021.
For more information about RxRevu, its solutions and innovative advancements, please contact a member of our team at firstname.lastname@example.org.
RxRevu is a Denver-based company on a mission to improve healthcare through more informed, consistent and frictionless prescription decisions. RxRevu’s Prescription Decision Support platform, SwiftRx®, allows healthcare providers to quickly and easily find patient-specific cheaper drugs. SwiftRx® also enables health systems to holistically manage and measure clinicians’ prescribing performance.
By Eric C. Naples, Esq.